Advertisement
Home »

CDN1163 alleviates SERCA2 dysfunction-induced pulmonary vascular remodeling by inhibiting the phenotypic transition of pulmonary artery smooth muscle cells.

Oct 30, 2023

ABOUT THE CONTRIBUTORS

  • Weimin Yu

    Institute of Health Biological Chemical Medication, Chongqing Institute of Green and Intelligent Technology, Chinese Academy of Sciences, Chongqing, China.

    School of Pharmaceutical Sciences, Chongqing University, Chongqing, China.

    Qian Zhang

    School of Pharmaceutical Sciences, Chongqing University, Chongqing, China.

    Yixiang Qiu

    School of Pharmaceutical Sciences, Chongqing University, Chongqing, China.

    Hui Chen

    School of Pharmaceutical Sciences, Chongqing University, Chongqing, China.

    Xiaoyang Huang

    School of Pharmaceutical Sciences, Chongqing University, Chongqing, China.

    Li Xiao

    School of Pharmaceutical Sciences, Chongqing University, Chongqing, China.

    Gang Xu

    Institute of Medicine and Equipment for High Altitude Region, College of High Altitude Military Medicine, Army Medical University (Third Military Medical University), Chongqing, China.

    Key Laboratory of High Altitude Medicine, People’s Liberation Army, Chongqing, China.

    Siqi Li

    School of Pharmaceutical Sciences, Chongqing University, Chongqing, China.

    Central Clinical School, Monash University, Melbourne, Australia.

    Pingping Hu

    College of Pharmacy, Chongqing Medical University, Chongqing, China.

    Xiaoyong Tong

    School of Pharmaceutical Sciences, Chongqing University, Chongqing, China.

    Jinfeng Laboratory, Chongqing, China.

REFERENCES & ADDITIONAL READING

PubMed

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement